Summary: Evaluated losartan versus atenolol in patients with previously untreated hypertension. The primary composite endpoint of cardiovascular death, fatal or nonfatal stroke, fatal and nonfatal MI was reduced by losartan compared to atenolol despite similar blood pressure reductions. Losartan was better tolerated than atenolol.
Lancet. 2002 Mar 23;359(9311):995-1003.
Lancet. 2002 Mar 23;359(9311):1004-10.
Eponym: Losartan Intervention For Endpoint Reduction Trial